PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 30, 2026Journal of Clinical Oncology

Utilization of CEACAM7 as a novel diagnostic biomarker of pancreatic cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

ADAnupam DhasmanaSDSwati DhasmanaSKSheema Khan

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates CEACAM7 as a potential biomarker for pancreatic cancer, suggesting improved diagnosis.

Key Points

  • This research aims to evaluate CEACAM7 as a specific diagnostic biomarker for pancreatic cancer, particularly PDAC.
  • Conducted bioinformatics analysis to investigate CEACAM7 expression in various cancers.
  • Determined CEACAM7 concentration in PDAC cell lines and pancreatic tumor tissues.
  • Assessed CEACAM7 levels in blood samples from pancreatic cancer patients and healthy individuals.
  • CEACAM7 is significantly higher in pancreatic cancer tissues than in healthy individuals.
  • Among PDAC cell lines, HPAF-II exhibited the highest CEACAM7 concentration (704.435 pg/ml).
  • Measurable CEACAM7 protein was found in the blood of pancreatic cancer patients, absent in healthy individuals.

Cite This Study

Dhasmana et al. (2026) studied this question.

synapsesocial.com/papers/6a1a818e0307b785094335cchttps://doi.org/10.1200/jco.2026.44.16_suppl.e16421
View Full Paper
Ask AI
Bookmark
Share